Australia’s Mayne Pharma has received a further setback in its efforts to gain approval for a generic version of Merck & Co’s top-selling, off-patent NuvaRing (etonogestrel/ethinylestradiol) contraceptive device in the US. The US Food and Drug Administration has issued the firm with a complete response letter relating to its application, after Mayne already responded to a previous CRL received two years ago. (Also see "Mayne Lines Up Two, But Misses Out On Myring" - Generics Bulletin, 20 December, 2018.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?